Page 227 - bandung_Neat

Judul : Bio Farma ensures Indonesians given priority in vaccine distribution

Nama Media : antaranews.com

Tanggal : 12 Agustus 2020

Halaman/URL : https://en.antaranews.com/news/153966/bio-farma-ensures-
indonesians-given-priority-in-vaccine-distribution

Tipe Media : Online

PT Bio Farma Director Honesti Basyir has
made assurance that Indonesians will be
prioritized during the distribution of the
COVID-19 vaccine after passing the clinical
trial period and securing permission for
production.

"The priority is for domestic (use) first," Basyir
stated at the Padjajaran Institute Hospital in
Bandung, West Java, on Tuesday.

As per calculations, 160 million Indonesians will be prioritized to receive the vaccine that
originated from China's Sinovac.

The Bio Farma director noted that each individual will have to be administered two doses
of the vaccination.

"Next year, the target is set to vaccinate 160 million members of the population, with
each individual receiving two doses, thereby translating to the fact that we will require to
prepare 320 million doses," he stated.

Basyir noted that once the vaccination requirements for Indonesians were met, Bio
Farma will then consider exporting the vaccine to other countries.

Currently, the company is awaiting the conclusion of the clinical trial process as well as
the licensing phase from the Food and Drug Supervisory Agency (BPOM) that is
targeted for completion in January 2021. Furthermore, Basyir stated that Bio Farma had
an annual production capacity of 100 million vaccines. By December 2020, the company
will have a new building, thereby leading to another 150 million doses being added to
their annual production.

"The president is looking at a new building that can result in the added production of 150
million doses per year. It will be completed in December. Thus, in terms of capacity, we
will be ready (to produce) 250 million doses in December," he expounded.

In the meantime, President Joko Widodo was optimistic that the vaccine, still under the
clinical trial phase, would be able to tackle the COVID-19 pandemic in Indonesia while
prioritizing its citizens.

"We are optimistic that with the finding of the vaccine, we would be able to distribute
vaccines to all Indonesians," he added.